12-Mar-2015 - Merck Serono International S.A.

Merck Serono and Illumina Enter Strategic Collaboration for Diagnostics in Oncology

Merck Serono and Illumina, Inc., announced a collaboration to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies.

Under the terms of the agreement, Merck Serono and Illlumina will work together to develop assays that detect and simultaneously measure multiple genetic variants in a single tumor sample in a clinical trial setting. Illumina’s successful regulatory track record was an important consideration in the collaboration, as next-generation sequencing platforms cleared by a regulatory agency could accelerate the development of an assay and facilitate the registration of a companion diagnostic.

“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, Head of Global Business Development at Merck Serono. “This collaboration will strengthen the position of Merck Serono as a global leader in precision medicine in oncology.”

The collaboration will include development of the diagnostic, worldwide regulatory approvals, and global commercialization.

Facts, background information, dossiers
  • Merck Serono
  • oncology
  • Illumina
  • next generation sequencing
  • diagnostics
  • cancer
More about Merck Serono
  • News

    Merck on Track with Pharma Strategy

    Merck announced that its biopharmaceutical division Merck Serono is well on track with the implementation of the Group’s “Fit for 2018” transformation and growth program. This is reflected by efficiency gains and the successful execution of growth initiatives as well as progress in the pipe ... more

More about Illumina